- Home
- REPL vs GERN Comparison
REPL vs GERN Comparison
Compare REPL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- GERN
- Stock Information
- Founded
- REPL 2015
- GERN 1990
- Country
- REPL United States
- GERN United States
- Employees
- REPL N/A
- GERN N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- REPL Health Care
- GERN Health Care
- Exchange
- REPL Nasdaq
- GERN Nasdaq
- Market Cap
- REPL 757.8M
- GERN 853.5M
- IPO Year
- REPL 2018
- GERN 1996
- Fundamental
- Price
- REPL $9.21
- GERN $1.40
- Analyst Decision
- REPL Strong Buy
- GERN Buy
- Analyst Count
- REPL 7
- GERN 7
- Target Price
- REPL $20.83
- GERN $4.17
- AVG Volume (30 Days)
- REPL 1.1M
- GERN 10.0M
- Earning Date
- REPL 08-07-2025
- GERN 08-07-2025
- Dividend Yield
- REPL N/A
- GERN N/A
- EPS Growth
- REPL N/A
- GERN N/A
- EPS
- REPL N/A
- GERN N/A
- Revenue
- REPL N/A
- GERN $116,293,000.00
- Revenue This Year
- REPL N/A
- GERN $160.12
- Revenue Next Year
- REPL N/A
- GERN $55.01
- P/E Ratio
- REPL N/A
- GERN N/A
- Revenue Growth
- REPL N/A
- GERN 22264.04
- 52 Week Low
- REPL $6.44
- GERN $1.17
- 52 Week High
- REPL $17.00
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- REPL 53.47
- GERN 42.89
- Support Level
- REPL $9.15
- GERN $1.36
- Resistance Level
- REPL $9.64
- GERN $1.57
- Average True Range (ATR)
- REPL 0.50
- GERN 0.09
- MACD
- REPL -0.06
- GERN -0.02
- Stochastic Oscillator
- REPL 50.57
- GERN 7.69
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.